Anti-angiogenesis therapy for the treatment of ovarian cancer

A technology for ovarian cancer and therapy, applied in the direction of anti-growth factor immunoglobulin, antibody, anti-tumor drugs, etc., can solve the problem of high mortality rate of cases

Inactive Publication Date: 2013-08-07
F HOFFMANN LA ROCHE & CO AG
View PDF52 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite advances in patient management, the disease still has a high death-t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-angiogenesis therapy for the treatment of ovarian cancer
  • Anti-angiogenesis therapy for the treatment of ovarian cancer
  • Anti-angiogenesis therapy for the treatment of ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0255] Example 1: Carboplatin and Paclitaxel plus Placebo vs. Carboplatin and Paclitaxel plus Concurrent Bevacizumab, followed by Placebo, Versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab Anti, stage III in women with newly diagnosed, previously untreated, stage III (suboptimal and macroscopically optimal massively resected) or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer test

[0256] Presents results from a phase III randomized study of patients with International Federation of Obstetrics and Gynecologic Oncology (FIGO) stages III and IV epithelial ovarian, primary peritoneal or fallopian tube cancer (epithelial ovarian, peritoneal primary or fallopian tube cancer). cancer) to evaluate new treatment procedures. The primary objective included determining the addition of 5 concurrent cycles of bevacizumab to 6 in women with newly diagnosed stage III (with any overall residual disease) and stage IV epithelial ovarian, primary pe...

Embodiment 2

[0310] Example 2. A randomized, two-arm, multicenter gynecologic cancer intergroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer

[0311] Results from a phase III randomized study (ICON7) to assess the safety and efficacy of adding bevacizumab to standard chemotherapy of carboplatin and paclitaxel are presented. The primary endpoint was determined in patients with newly diagnosed, histologically confirmed, high-risk International Federation of Gynecology and Obstetrics (FIGO) stages I and IIa (grade 3 or only clear cell carcinoma) and FIGO stages IIb-IV (all grades and All histologic types) epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have undergone primary surgery (massive excisional cytoreductive surgery or biopsy if patient has FIGO stage IV disease) and will not be diagnosed before disease progression Whether the addition of bevacizumab to standard chemotherapy improves...

Embodiment 3

[0402] Example 3. A phase III, multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

Description

[0001] related application [0002] This application claims U.S. Provisional Application Serial No. 61 / 439,819 filed February 4, 2011; U.S. Provisional Application Serial No. 61 / 360,059 filed June 30, 2010; U.S. Provisional Application Serial No. filed June 3, 2010 61 / 351,231; and the priority and benefit of U.S. Provisional Application Serial No. 61 / 307,095, filed February 23, 2010, the specification of which is incorporated herein in its entirety. field of invention [0003] In general, the present invention relates to the treatment of human diseases and pathological conditions. More specifically, the present invention relates to anti-angiogenic therapy, either alone or in combination with other anti-cancer therapies, for the treatment of ovarian cancer. Background of the invention [0004] Cancer remains one of the deadliest threats to human health. Cancer affects nearly 1.3 million new patients each year in the United States and is the second leading cause of death aft...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/22A61K31/282A61K31/337A61K39/395
CPCC07K16/22A61K39/39558A61K31/282A61K39/3955A61K31/7068G06Q99/00A61K31/337A61P15/00A61P35/00A61P43/00A61K2300/00C07K2317/56C07K16/3069C07K2317/24A61K2039/545A61K2039/54A61K9/0019A61K45/06
Inventor J.杜邦C.伊尔
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap